{"prompt": "['Novartis', 'Confidential', 'Page 10', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'Study treatment', 'When the patient permanently stops taking study treatment prior to', 'discontinuation (TD)', 'the defined study treatment completion date', 'Variable', 'A measured value or assessed response that is determined in', 'specific assessments and used in data analysis to evaluate the drug', 'being tested in the study', 'Withdrawal of consent (WoC)', 'Withdrawal of consent from the study is defined as when a patient', 'does not want to participate in the study any longer, and does not', 'want any further visits or assessments, and does not want any', 'further study related contact, and does not allow analysis of already', 'obtained biologic material']['Novartis', 'Confidential', 'Page 11', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'Protocol summary', 'Protocol number', 'CQAW039A2316', 'Full title', 'A 12-week, multicenter, randomized, double-blind, placebo-controlled study', 'to assess the efficacy and safety of QAW039 when added to standard-of-', 'care asthma therapy in patients with uncontrolled asthma', 'Brief title', 'Study of efficacy and safety of QAW039 when added to standard-of-care', 'asthma therapy in patients with uncontrolled asthma', 'Sponsor and clinical', 'Novartis, Phase 3', 'phase', 'Investigation type', 'Drug', 'Study type', 'Interventional', 'Purpose and rationale', 'The purpose of this study is to determine the efficacy and safety of', 'QAW039 (150 mg once daily), compared with placebo, when added to', 'standard-of-care (SoC) asthma therapy in adult and adolescent ( 12', 'years) patients with uncontrolled asthma with respect to change from', 'baseline in forced expiratory volume in 1 second (FEV1) at the end of 12', 'weeks of treatment.', 'Primary objective', 'To demonstrate the efficacy of QAW039 150 mg once daily as measured', 'by change from baseline in pre-dose FEV1 [in liters], compared with', 'placebo, at the end of the 12-week active-treatment period.', 'Secondary objectives', '1.', 'To demonstrate the efficacy of QAW039 150 mg once daily, compared', 'with placebo, on daytime asthma symptoms over the 12-week', 'active-treatment period.', '2. To demonstrate the efficacy of QAW039 150 mg once daily, compared', 'with placebo, on total daily short-acting \u00df-agonist (SABA) use over the 12-', 'week active-treatment period.', '3. To demonstrate the efficacy of QAW039 150 mg once daily, compared', 'with placebo, on change from baseline in Asthma Quality of Life', 'Questionnaire for 12 years and older (AQLQ+12) scores at the end of the', '12-week active-treatment period.', '4. To assess the safety of QAW039 150 mg once daily, compared with', 'placebo, with respect to adverse events (AEs), electrocardiograms (ECGs),', 'vital signs and laboratory tests.', 'Study design', 'This study uses a randomized, multicenter, double-blind, placebo-', 'controlled, parallel-group study design.', 'Population', 'The study population will include:', 'Males and females aged >12 years.', 'Asthma patients who are already receiving ICS or ICS with one asthma', 'controller medication (see inclusion criterion 4 for allowed ICS doses', 'and combinations) are the target population for this study.', 'Key inclusion criteria', 'Patients must have a diagnosis of asthma (according to GINA 2016) for', 'a period of at least 6 months prior to Visit 1.', 'Patients who have been treated with:', 'Medium dose ICS, or', 'High dose ICS, or', 'Low dose ICS plus long-acting beta agonist (LABA), or', 'Low dose ICS plus leukotriene receptor antagonist (LTRA), or']['Novartis', 'Confidential', 'Page 12', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'Medium dose ICS plus LABA.', 'for at least 3 months prior to Visit 1 and the doses have been stable for at', 'least 4 weeks prior to Visit 1.', 'For patients aged >18 years, FEV1 of <85% of the predicted normal', 'value for the patient, after withholding bronchodilators at Visit 1 and', 'Visit 101. For patients aged 12 to <18 years, FEV1 of <90% of the', 'predicted normal value for the patient, after withholding bronchodilators', 'at Visit 1 and Visit 101.', 'Patients must have a daytime asthma symptom score (0 to 6 scale) of', '1 per day during 4 of the last 7 days of the placebo run-in period.', 'Patients must have a total daily SABA use 1 puff per day during 4 of', 'the last 7 days of the placebo run-in period.', 'Demonstrated reversible airway obstruction as determined by the', 'central reader from the spirometry vendor at Visit 1 or Visit 101.', 'Reversibility is defined as an increase of 12% and >200 ml in FEV1', 'approximately 10 to 15 minutes after administration of 400 mcg of', 'salbutamol/albuterol (or equivalent). Spacer devices are permitted for', 'administration of salbutamol/albuterol (or equivalent) during reversibility', 'testing only. The Investigator or delegate may decide whether or not to', 'use a spacer for the reversibility testing.', 'If reversibility is not demonstrated at Visit 1, reversibility will be', 'attempted at Visit 101. If not achieved at Visit 101, one additional', 'attempt to demonstrate reversibility is permitted within 4 days', 'following Visit 101 in an ad-hoc visit to meet this eligibility criterion.', 'Review Visit 1 or Visit 101 or the one additional attempt reversibility', 'result from overread by the spirometry vendor central reader prior', 'to randomization.', 'An asthma control questionnaire (ACQ) score 1.5 at Visit 199.', 'Key exclusion criteria', 'Use of other investigational drugs within 5 half-lives of enrollment, or', 'within 30 days, whichever is longer.', 'Patients with a resting QTcF (Fridericia) >450 msec (male) or >460', 'msec (female) at Visit 1.', 'Patients with a history of malignancy of any organ system (other than', 'localized basal cell carcinoma of the skin or in situ cervical cancer),', 'treated or untreated, within the past 5 years, regardless of whether', 'there is evidence of local recurrence or metastases', 'Pregnant or nursing (lactating) women, where pregnancy is defined as', 'the state of a female after conception and until the termination of', 'gestation, confirmed by a positive human chorionic gonadotropin (hCG)', 'laboratory test.', 'Women of child-bearing potential, defined as all women physiologically', 'capable of becoming pregnant, unless they are using basic methods of', 'contraception during dosing of study drug.', 'Patients who have a clinically significant laboratory abnormality at the', 'Visit 1 laboratory test.', 'Patients with serious co-morbidities including, but not limited to,', 'neurodegenerative diseases, rheumatoid arthritis and other', 'autoimmune diseases.', 'Patients on >20 mg of simvastatin, > 40 mg of atorvastatin, >40 mg of', 'pravastatin, or >2 mg of pitavastatin. Statin doses less than or equal to']\n\n###\n\n", "completion": "END"}